Compounds > 3-(2,2,2-trimethylhydrazine)propionate
Page last updated: 2024-09-03

3-(2,2,2-trimethylhydrazine)propionate and Cerebrovascular Disorders

3-(2,2,2-trimethylhydrazine)propionate has been researched along with Cerebrovascular Disorders in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Bolotova, TA; Fedin, PA; Maksimova, MY; Medvedev, RB; Shabalina, AA; Tanashyan, MM1
Afanas'ev, VV; Murashko, NK1

Other Studies

2 other study(ies) available for 3-(2,2,2-trimethylhydrazine)propionate and Cerebrovascular Disorders

ArticleYear
[Chronic cerebrovascular diseases and neuroprotection: the clinical efficacy of meldonium (Mildronat)].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2020, Volume: 120, Issue:10

    Topics: Cerebrovascular Disorders; Humans; Methylhydrazines; Neuroprotection; Quality of Life; Tissue Plasminogen Activator; Treatment Outcome

2020
[Mildronat--treatment of cardio-neurologic pathology in ischemia and hypoxia].
    Likars'ka sprava, 2012, Issue:7

    Topics: Cardiovascular Agents; Cardiovascular Diseases; Cerebrovascular Circulation; Cerebrovascular Disorders; Energy Metabolism; Humans; Hypoxia; Ischemia; Methylhydrazines; Randomized Controlled Trials as Topic

2012